Neurogene Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Neurogene Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $22.00K, a 67.65% decline year-over-year.
- Neurogene Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $201.00K, a 957.89% increase year-over-year.
- Neurogene Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $89.00K, a 37.76% decline year-over-year.
- Neurogene Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $68.00K, a 83.61% decline year-over-year.
- Neurogene Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $266.00K, a 84.13% decline from fiscal 2024.
- Neurogene Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $1.68M, a 897.62% increase from fiscal 2023.
- Neurogene Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $168.00K, a 130.14% increase from fiscal 2022.
- Neurogene Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $73.00K, a 82.24% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $22.00K 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $201.00K 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $266.00K 10-K · filed 2026-03-24 | |
| 2025-09-30 | $89.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $68.00K 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $19.00K 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $1.68M 10-K · filed 2026-03-24 | |
| 2024-09-30 | $143.00K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $415.00K 10-Q · filed 2025-11-13 | |
| 2024-03-31 | $629.00K 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $168.00K 10-K · filed 2025-03-24 | |
| 2023-09-30 | $35.00K 10-Q · filed 2024-11-18 | |
| 2023-06-30 | $20.00K 10-Q · filed 2024-11-18 | |
| 2023-03-31 | $112.00K 10-Q · filed 2024-11-18 | |
| 2022-12-31 | $73.00K 10-K · filed 2024-03-18 | |
| 2022-03-31 | $134.00K 10-Q · filed 2023-11-14 | |
| 2021-12-31 | $411.00K 10-K · filed 2023-03-20 | |
| 2021-09-30 | $31.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $95.00K 10-Q · filed 2022-11-14 | |
| 2021-03-31 | $282.00K 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $5.67M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $882.00K 10-Q · filed 2021-11-04 | $6.09M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $303.00K 10-Q · filed 2021-11-04 | $5.25M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-03-31 | $3.39M 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $1.55M 10-K · filed 2021-03-25 |
| 2019-09-30 | $40.00K 10-Q · filed 2020-11-09 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $602.00K 10-K · filed 2020-03-12 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | |
| 2018-06-30 | $399.00K 10-Q · filed 2019-08-01 | |
| 2018-03-31 | $203.00K 10-Q · filed 2019-05-07 | |
| 2017-12-31 | $468.00K 10-K · filed 2020-03-12 | |
| 2016-12-31 | $440.00K 10-K · filed 2019-03-07 | |
| 2015-12-31 | $1.12M 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |